'Sig­nif­i­cant ques­tions re­main' on ap­proval of Bio­gen's new Alzheimer's drug, con­gres­sion­al com­mit­tees tell FDA

Two promi­nent House com­mit­tees are dig­ging deep­er in­to the FDA’s cozy re­la­tion­ship with Bio­gen as it re­viewed and ap­proved its new Alzheimer’s drug Aduhelm. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER